Melarsomine Dihydrocloride Injectable 25Mg/Ml
612 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
612
Total Reports
23
Deaths Reported
380.0%
Death Rate
Active Ingredients
Melarsomine Dihydrocloride Injectable 25Mg/Ml
Administration Routes
IntramuscularUnknownSubcutaneousIntravenous
Species Affected
Dog 502
Unknown 106
Human 3
Other Canids 1
Most Affected Breeds
Unknown 109
Dog (other) 82
Retriever - Labrador 62
Crossbred Canine/dog 33
Dog (unknown) 27
Shepherd Dog - German 19
Boxer (German Boxer) 19
Chihuahua 19
Pit Bull 17
Beagle 17
Most Reported Reactions
INEFFECTIVE, HEARTWORM ADULTS 127
Vials, Damaged 78
Vomiting 67
Lethargy (see also Central nervous system depression in 'Neurological') 61
INEFFECTIVE, HEARTWORM LARVAE 41
Injection site swelling 38
Panting 37
Injection site lump 36
Injection site pain 36
Elevated alanine aminotransferase (ALT) 29
Other abnormal test result NOS 27
Lack of efficacy - NOS 26
Outcome Breakdown
Outcome Unknown
317 (62.4%)
Ongoing
74 (14.6%)
Recovered/Normal
54 (10.6%)
Recovered with Sequela
40 (7.9%)
Died
16 (3.1%)
Euthanized
7 (1.4%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.